Anti-Rheumatic Drugs - Poland

Poland

In Poland, the revenue in the Anti-Rheumatic Drugs market is estimated to reach US$86.99m in 2024.
It is expected that the revenue will have an annual growth rate (CAGR 2024-2029) of 0.48%, leading to a market volume of US$89.12m by 2029.
When compared globally, United States is projected to generate the highest revenue in the market, with US$34,700.00m in 2024.
Poland is experiencing a rising demand for biologic anti-rheumatic drugs due to the increasing prevalence of rheumatoid arthritis in the country.

Key regions: Germany, United States, India, Japan, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Rheumatic Drugs market in Poland has been experiencing steady growth in recent years.

Customer preferences: Patients suffering from rheumatoid arthritis in Poland prefer to use biologic drugs due to their effectiveness in managing pain, inflammation and slowing down the progression of the disease. This preference has led to an increase in the demand for biologic drugs in the country.

Trends in the market: The Anti-Rheumatic Drugs market in Poland is being driven by the increasing prevalence of rheumatoid arthritis in the country. This has led to an increase in the demand for drugs that can effectively manage the symptoms of the disease. The market has also been experiencing a shift towards biologic drugs due to their effectiveness in managing the disease. The market is expected to continue growing as the population ages and the prevalence of rheumatoid arthritis increases.

Local special circumstances: The Polish government has been implementing policies aimed at reducing the cost of healthcare in the country. This has led to the introduction of generic drugs into the market, which has increased competition and lowered the cost of drugs. The introduction of biosimilars has also contributed to the growth of the market as they are cheaper alternatives to biologic drugs.

Underlying macroeconomic factors: The Polish economy has been growing steadily in recent years, which has led to an increase in the standard of living of the population. This has led to an increase in the demand for healthcare services, including drugs for managing rheumatoid arthritis. The government has also been investing in the healthcare sector, which has led to an improvement in the quality of healthcare services in the country.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.